Second attempt to stop treatment after pioglitazone in CML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if a short course of pioglitazone (a diabetes drug) before stopping your TKI therapy can help you stay in remission longer. It is for people with chronic myeloid leukemia (CML) who have already lost their remission after a first or later attempt to stop TKI treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CML and are currently in a very deep remission (MR4).
- You previously lost your remission after stopping a TKI medicine (like imatinib, dasatinib, nilotinib, or bosutinib).
- You are at least 18 years old.
- Your liver and kidney function are within acceptable limits per blood tests.
- You are not pregnant, and you agree to use effective birth control if needed.
- You are not taking diabetes medicines for high blood sugar.
- You have no history of certain heart conditions, bladder cancer, or eye swelling (macular edema).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new, highly sensitive blood test (digital PCR) to find BCR::ABL1 mutations in people with chronic-phase CML who are switching their tyrosine kinase inhibitor (TKI) because of resistance or a warning sign. The goal is to see if this test can help guide treatment decisions more precisely.
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This trial tests a new daily tablet (TQB3911) for people with chronic myeloid leukemia (CML) whose current targeted therapy (TKI) has stopped working or caused side effects. The goal is to see if this new drug is safe and can better control the leukemia.
Hear when a new Chronic Myeloid Leukemia (CML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.